Osimertinib for EGFR-Mutated Lung Cancer: — Side Effects, Duration and What to Expect

T790M is the most common resistance mutation that develops when first- or second-generation EGFR TKIs stop working. It is found in a significant proportion of people whose cancer progresses on an earlier EGFR drug. Osimertinib was originally developed specifically to target T790M and remains the standard NCCN-recommended option in this setting. A tissue biopsy or liquid biopsy is usually done to confirm the mutation before switching treatment.

The rash can be noticeable, particularly on the face, scalp and upper body, and some people find it affects their confidence. It is not infectious and not an allergy — it is the drug's off-target effect on skin cells. Your oncology nurse or dermatologist can recommend a moisturising routine and, when needed, a topical antibiotic or steroid cream. Most rashes remain mild to moderate and do not require stopping the drug. Tell your team early rather than waiting until it becomes uncomfortable.

Several medicines can affect how osimertinib is processed in the body, including some antibiotics, antifungals, seizure medicines and stomach acid drugs — particularly proton pump inhibitors and H2 blockers. Always give your oncologist and pharmacist a complete list of every tablet, supplement, vitamin and herbal remedy you are taking, including anything from an ayurvedic or naturopathic practitioner. Grapefruit and Seville orange can also interact with many oral cancer drugs — your team will tell you whether this applies to your regimen.

Interstitial lung disease or pneumonitis — inflammation of the lung tissue — is rare but serious. New breathlessness, a dry cough or worsening exercise tolerance needs same-day contact with your team, not a wait for your next appointment. A small proportion of people develop changes in heart rhythm or reduced heart function, which is why ECG monitoring may be part of your care. Eye inflammation causing pain or visual change also needs same-day review. None of these are common, but acting early is what keeps them manageable.

In most cases, yes. Mild to moderate side effects are managed through adjusting skincare, diet or — when needed — the dose, rather than stopping the drug. NCCN toxicity guidance supports dose reduction as an intermediate step before discontinuation for many of the common reactions. Only a serious reaction such as significant lung inflammation, major heart changes or a severe unmanageable toxicity typically leads to holding or stopping treatment. Your team makes this assessment based on what they observe — which is why reporting side effects early, rather than tolerating them quietly, is so important.

Osimertinib is not safe during pregnancy. It carries a real potential to harm a developing baby, and effective contraception is recommended for people of childbearing potential throughout treatment and for a period after the last dose. If there is any possibility of pregnancy before starting, tell your oncologist immediately. Breastfeeding is not recommended during treatment. These are not administrative formalities — they reflect a documented risk — and your team can discuss the specifics in relation to your situation, including contraception options.